Buy Like Buffett
Watchlist

Flagship explainer

How Dare Bioscience, Inc. makes its money

Start with a dollar of revenue and follow what the filing says remains.

revenueBranching filed flows with values and percentages directly labeled. Missing filing concepts are omitted rather than estimated.Revenue$1M · 100%Cost of revenue$295799 · 29%Gross profit$734394 · 71%Operating income−$13.6M · −1316%Income before tax−$13.5M · −1314%Income tax$0 · 0%Net income−$13.4M · −1301%As of 2025-12-31 · 1 SEC filing sourceBuy Like Buffett · buylikebuffett.com

Honest partial: the filing did not provide a normalized tag for Research and development, Selling, general and administrative; those components are omitted, not plugged.

Table alternative
Filed lineValue% of revenueSource
$1M100%
  • 10-K · FY 2025Filing detailsAccession 0001401914-26-000004 · filed Mar 26, 2026
Cost of revenue$29579929%
  • 10-K · FY 2025Filing detailsAccession 0001401914-26-000004 · filed Mar 26, 2026
$73439471%
  • 10-K · FY 2025Filing detailsAccession 0001401914-26-000004 · filed Mar 26, 2026
−$13.6M−1316%
  • 10-K · FY 2025Filing detailsAccession 0001401914-26-000004 · filed Mar 26, 2026
Income before tax−$13.5M−1314%
  • 10-K · FY 2025Filing detailsAccession 0001401914-26-000004 · filed Mar 26, 2026
Income tax$00%
  • 10-K · FY 2025Filing detailsAccession 0001401914-26-000004 · filed Mar 26, 2026
−$13.4M−1301%
  • 10-K · FY 2025Filing detailsAccession 0001401914-26-000004 · filed Mar 26, 2026
Source:
  • 10-K · FY 2025Filing detailsAccession 0001401914-26-000004 · filed Mar 26, 2026
· event Dec 31, 2025 · retrieved Oct 18, 2026 · annual-row source set
Embed this chart

View the full Dare Bioscience, Inc. analysis at Buy Like Buffett